This prospective observational study aims to evaluate serum ADA, as a potential biomarker in adult patients with advanced and delayed pulmonary tuberculosis, with emphasis on its distribution in relation to cavitary lung lesions, bacteriological confirmation, and mortality—clinical features indicative of severe disease progression. This evidence concerns the gene ADA and pulmonary tuberculosis.